SK Biopharm seeks USFDA’s approval for new drug candidate
[DISCLOSURE] SK (034730) announced on Nov. 26 that its subsidiary SK Biopharm has handed in new drug application for US Food and Drug Administration’s approval for its novel epilepsy drug candidate Cenobamate.
By Hwang You-mee (glamazon@heraldcorp.com)